The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
Open accessAbstract
Cancer initiation and progression are the result of genetic and/or epigenetic alterations. Acetylation-mediated histone/non-histone protein modification plays an important role in the epigenetic regulation of gene expression. Histone modification is controlled by the balance between histone acetyltransferase and (HAT) and histone deacetylase (HDAC) enzymes. Imbalance between the activities of these two enzymes is associated with various forms of cancer. Histone deacetylase inhibitors (HDACi) regulate the activity of HDACs and are being used in cancer treatment either alone or in combination with other chemotherapeutic drugs/radiotherapy. The Food and Drug Administration (FDA) has already approved four compounds, namely vorinostat, romidepsin, belinostat, and panobinostat, as HDACi for the treatment of cancer. Several other HDACi of natural and synthetic origin are under clinical trial for the evaluation of efficiency and side-effects. Natural compounds of plant, fungus, and actinomycetes origin, such as phenolics, polyketides, tetrapeptide, terpenoids, alkaloids, and hydoxamic acid, have been reported to show potential HDAC-inhibitory activity. Several HDACi of natural and dietary origin are butein, protocatechuic aldehyde, kaempferol (grapes, green tea, tomatoes, potatoes, and onions), resveratrol (grapes, red wine, blueberries and peanuts), sinapinic acid (wine and vinegar), diallyl disulfide (garlic), and zerumbone (ginger). HDACi exhibit their antitumor effect by the activation of cell cycle arrest, induction of apoptosis and autophagy, angiogenesis inhibition, increased reactive oxygen species generation causing oxidative stress, and mitotic cell death in cancer cells. This review summarizes the HDACs classification, their aberrant expression in cancerous tissue, structures, sources, and the anticancer mechanisms of HDACi, as well as HDACi that are either FDA-approved or under clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 6×
“Phenyl butyrate Class I and II Solid and hematological tumors Phase I and II trial [118]”
BackgroundInfluentialHDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · cited 1×
“Acetylation also affects the activity of retinoblastoma protein (pRB) by blocking its cyclin E-cdk2 dependent phosphorylation so acetylation-dependent hypophosphorylation causes cell cycle arrest [26,27].”
BackgroundMammalian thioredoxin is a direct inhibitor of apoptosis signal‐regulating kinase (ASK) 1
Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., Tobiume, K., Sawada, Y., Kawabata, M., Miyazono, K., & Ichijo, H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.9.2596 · Cited by 2,377
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542 · cited 1×
“At lower concentrations HDACi predominately induces G1 arrest while at higher concentrations induces both G1 and G2/M arrest [123].”
BackgroundNew and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Nutrient-Sensitive Mitochondrial NAD+ Levels Dictate Cell Survival
Yang, H., Yang, T., Baur, J. A., Perez, E., Matsui, T., Carmona, J. J., Lamming, D. W., Souza-Pinto, N. C., Bohr, V. A., Rosenzweig, A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.035 · Cited by 950 · cited 1×
“SIRT 7 KD results in the tumorigenic potential of human cancer xenograft in mice [77].”
BackgroundThree proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770 · cited 1×
“While HDACs 4, 5, and 6 were first reported in 1999, the HDAC 7 was discovered in early 2000 and so on [21,22].”
Background
Cited by
Resveratrol: A Double-Edged Sword in Health Benefits
Salehi, B., Mishra, A. P., Nigam, M., Sener, B., Kilic, M., Sharifi-Rad, M., Fokou, P. V. T., Martins, N., & Sharifi-Rad, J. (2018) · Biomedicines · doi:10.3390/biomedicines6030091 · Cited by 1,129
Kumar Singh, A., Cabral, C., Kumar, R., Ganguly, R., Kumar Rana, H., Gupta, A., Rosaria Lauro, M., Carbone, C., Reis, F., & Pandey, A. K. (2019) · Nutrients · doi:10.3390/nu11092216 · Cited by 433
Self-citationThe Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Li, G., Tian, Y., & Zhu, W.-G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576946 · Cited by 352
Targeting epigenetic regulators to overcome drug resistance in cancers
Wang, N., Ma, T., & Yu, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01341-7 · Cited by 311
Nutritional implications of ginger: chemistry, biological activities and signaling pathways
Kiyama, R. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108486 · Cited by 288
Recent histone deacetylase inhibitors in cancer therapy
Parveen, R., Harihar, D., & Chatterji, B. P. (2023) · Cancer · doi:10.1002/cncr.34974 · Cited by 171
“The four substances—vorinostat, romidepsin, belinostat, and panobinostat— have been previously authorized by the Food and Drug Administration (FDA) as the HDACi for the management of cancer among which HDACi based on hydroxamic acid were the first class to be developed.(12) Belinostat, the second hydroxamic acid‐ base…”
BackgroundDietary Management of Obesity: A Review of the Evidence
Hwalla, N., & Jaafar, Z. (2020) · Diagnostics · doi:10.3390/diagnostics11010024 · Cited by 66
Arresting the bad seed: HDAC3 regulates proliferation of different microglia after ischemic stroke
Zhang, Y., Li, J., Zhao, Y., Huang, Y., Shi, Z., Wang, H., Cao, H., Wang, C., Wang, Y., Chen, D., et al. (2024) · Science Advances · doi:10.1126/sciadv.ade6900 · Cited by 55
“Although a recent investigation has indicated that HDAC3 inhibition disrupts the activity of CENP-F (encoded by Cenpf ) ( 46 ), comprehensive elucidation of how HDAC3 directly modulates the mRNA levels of these cell cycle–related genes remains largely unexplored.”
BackgroundAlquezar, C., Schoch, K. M., Geier, E. G., Ramos, E. M., Scrivo, A., Li, K. H., Argouarch, A. R., Mlynarski, E. E., Dombroski, B., DeTure, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg3897 · Cited by 56
Ghiboub, M., Elfiky, A. M. I., de Winther, M. P. J., Harker, N. R., Tough, D. F., & de Jonge, W. J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050336 · Cited by 28
Xu, J., Guan, X., Jia, X., Li, H., Chen, R., & Lu, Y. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100255 · Cited by 19
“Deacetylases are being extensively investigated as anticancer drug targets (50), and there has been a great interest to explore their functions in various biological contexts.”
Background
Metadata
- Authors
- Singh, A. K., Bishayee, A., & Pandey, A. K.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2018-06-06
- Volume
- 10
- Issue
- 6
- Pages
- 731
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W2805590406
- Cited by
- 221
- References
- 17
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.